Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1161 | Thyroid 3 | ECE2019

Do patients with differentiated thyroid cancer (DTC) harboring TERT promoter mutation require a more intensive treatment and follow-up? – proposal of a prospective study

Samborski Konrad , Krajewska Jolanta , Rusinek Dagmara , Oczko-Wojciechowska Magdalena , Jarzęb Barbara

Introduction: The importance of telomerase reverse transcriptase promoter (TERTp) mutations in DTC is widely discussed. It has been demonstrated that the presence of TERTp mutations is associated with higher cancer aggressiveness, reflected by lymph node metastases, distant metastases, advanced tumor stage, recurrence, and even disease-specific mortality. Nevertheless, there is no clear evidence-based data demonstrating how to manage these patients. Therefore...

ea0092ps1-01-09 | Cancer | ETA2023

Risk of renal adverse effects in patients with advanced thyroid cancer who are undergoing radiological monitoring, with a particular focus on patients receiving tyrosine kinase inhibitors

Haras-Gil Malgorzata , Samborski Konrad , Ledwon Aleksandra , Kolton Magdalena , Handkiewicz-Junak Daria , Jarzab Barbara , Krajewska Jolanta

Introduction: Systemic treatment of advanced progressing thyroid cancer (TC) is based on molecularly targeted therapy with tyrosine kinase inhibitors (TKIs), mainly inhibitors targeting vascular endothelial growth factor receptors (VEGFR). Such treatment is related to numerous side effects. However, the relationship between TKIs and renal adverse events (RAEs) is unclear. VEGFR inhibitors are associated with proteinuria. In some patients, increased serum creatinine level and t...